EP2298331A3
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
Abstract
The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.
Term
Term ended
Projected expiry passed 3 April 2023, 3.5 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 1 of 2
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| US5714142A | Cites | United States of America | AD | Search report | 1-15 |
20 members in 9 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 117109 | United States of America | – | |
| 11710902 | United States of America | A | |
| 03721538 | European Patent Office (EPO) | A | |
| 03721538 | – | – | – |
| 117109 | – | – | – |
| EP20030721538 | – | – | – |
| US20020117109 | – | – | – |
Members20
| Document | Office | Kind | |
|---|---|---|---|
| US2003191056A1 | United States of America | A1 | |
| US2003195154A1 | United States of America | A1 | |
| CA2480883A1 | Canada | A1 | |
| WO03086444A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2003224844A1 | Australia | A1 | |
| MXPA04009680A | Mexico | A | |
| EP1496926A1 | European Patent Office (EPO) | A1 | |
| PL372849A1 | Poland | A1 | |
| JP2005529108A | Japan | A | |
| EP1496926A4 | European Patent Office (EPO) | A4 | |
| AU2003224844B2 | Australia | B2 | |
| US2009191624A1 | United States of America | A1 | |
| EP2298331A2 | European Patent Office (EPO) | A2 | |
| EP2298331A3This record | European Patent Office (EPO) | A3 | |
| JP2011136981A | Japan | A | |
| JP4738743B2 | Japan | B2 | |
| EP1496926B1 | European Patent Office (EPO) | B1 | |
| ES2400341T3 | Spain | T3 | |
| US8633153B2 | United States of America | B2 | |
| US2014234945A1 | United States of America | A1 |
11 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application deemed to be withdrawnWithdrawn18D | 18D | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | |
| First examination report despatched17Q | 17Q | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Divisional application: reference to earlier applicationAC | AC | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 2298331
- Publication, DOCDB
- 2298331
- Publication, EPODOC
- EP2298331
- Application
- 10178081
- Application, DOCDB
- 10178081
- Application, EPODOC
- EP20100178081
Titles3
- German
- Verwendung von Transthyretinpeptid-/-proteinfusionen zur Erhöhung der Serumshalbwertszeit von pharmakologisch aktiven Peptiden/Proteinen
- English
- Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
- French
- Utilisation de fusions de peptides/protéines de transthyrétine pour augmenter la demi-vie sérique de peptides/protéines pharmacologiquement actifs
Classification
- CPC, 14
- A61K38/043
- C07K14/47
- A61K38/10
- A61K38/20
- A61K38/29
- A61K47/58
- A61K47/60
- A61K47/61
- A61K47/643
- A61P3/10
- A61P5/18
- A61P7/04
- A61P9/12
- C07K2319/31
- IPC, 16
- A61K38 00
- A61K47 48
- C12N15 09
- A61K38 17
- A61K38 44
- A61K47 32
- A61K47 34
- A61K47 36
- A61K47 42
- A61P3 10
- A61P7 04
- C07K14 435
- C07K14 475
- C07K14 605
- C07K17 08
- C07K19 00
Designated states31
- Contracting states, 27
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Romania
- Sweden
and 3 moreShow fewer
- Slovenia
- Slovakia
- Türkiye
- Extension states, 4
- Albania
- Lithuania
- Latvia
- North Macedonia